Short Interest in IQVIA Holdings Inc. (NYSE:IQV) Declines By 20.6%

IQVIA Holdings Inc. (NYSE:IQV) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 3,735,524 shares, a decrease of 20.6% from the December 15th total of 4,704,477 shares. Currently, 2.2% of the company’s shares are short sold. Based on an average trading volume of 1,165,163 shares, the days-to-cover ratio is currently 3.2 days. Based on an average trading volume of 1,165,163 shares, the days-to-cover ratio is currently 3.2 days. Currently, 2.2% of the company’s shares are short sold.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the last quarter. Westside Investment Management Inc. grew its holdings in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA during the third quarter valued at approximately $30,000. Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA in the third quarter valued at $36,000. Finally, Root Financial Partners LLC acquired a new stake in IQVIA during the third quarter worth $43,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.3%

Shares of NYSE:IQV opened at $238.03 on Friday. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a fifty day moving average price of $227.30 and a 200 day moving average price of $203.34. The stock has a market capitalization of $40.54 billion, a PE ratio of 32.65, a P/E/G ratio of 2.42 and a beta of 1.36. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Evercore ISI upped their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. UBS Group increased their price target on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $249.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.